Monoclonal Anti-Vascular Endothelial Growth Factor Receptor-1 antibody produced in mouse

Monoclonal Anti-Vascular Endothelial Growth Factor Receptor-1 antibody produced in mouse has been used in:

• immunofluorescence labelling
• enzyme-linked immunosorbent assay (ELISA)
• immunohistochemistry
• immunoprecipitation

Mouse monoclonal clone FLT-19 anti-Vascular Endothelial Growth Factor Receptor-1 antibody may be used for the localization of VEGF-R1 using various immunochemical assays such as ELISA, immunoblotting, immunocytochemistry, immunohistochemistry, and immunoprecipitation. Antibodies that react specifically with VEGF receptors are useful for the study of the specific differential tissue expression and intracellular localization of the receptor in normal and neoplastic tissue.

The mitogenic activity of VEGF appears to be stimulated by specific VEGF receptors (160-200 kDa) which can be found on the surface of various endothelial cells. VEGF binds to two structurally similar receptor tyrosine kinases; Flt1 (fms-like tyrosine kinase 1, also known as VEGF Receptor-1 (VEGF-R1), and KDR (kinase insert domain containing receptor, also known as VEGF-R2). Studies using KDR and Flt1 stably transfected endothelial cell lines have shown that these two receptors exhibit different affinities to VEGF and mediate different responses. KDR/Flk1 does not respond to placental growth factor (PlGF), a VEGF related growth factor, while Flt1 binds PlGF specifically. Flt1 is predominately expressed in human placenta and human vascular endothelial cells. Both VEGF receptors (KDR and Flt1) are upregulated in human fetal and adult kidney.

Vascular endothelial growth factor (VEGF) stimulates the proliferation of endothelial cells isolated from both small and large vessels.

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Monoclonal Anti-VEGF Receptor-1 (Flt1 Receptor) (mouse IgG1 isotype) is derived from the FLT-19 hybridoma produced by the fusion of mouse myeloma cells and splenocytes from BALB/c mice immunized with a recombinant extracellular domain of VEGF Receptor-1 (Flt1 Receptor) of human origin. Vascular endothelial growth factor (VEGF), also called vasculotropin (VAS)1 and vascular permeability factor (VPF) 2 is a member of a family of endothelial cell mitogens and angiogenic factors. VEGF is a homodimeric heparin-binding glycoprotein. VEGF binds to two structurally similar receptor tyrosine kinases; Flt15 (fms-like tyrosine kinase 1, also termed VEGF Receptor-1, VEGF-R1) and KDR6 (kinase-insert domain containing receptor, also termed VEGF-R2). Flt1 is predominately expressed in human placenta and human vascular endothelial cells, while KDR is more widely expressed in all vessel-derived endothelial cells but low in human and fetal bovine placenta.

Mouse monoclonal clone FLT-19 anti-Vascular Endothelial Growth Factor Receptor-1 antibody recognizes the extracellular domain of human VEGF Receptor-1 molecule (Flt1 Receptor). The antibody does not recognize VEGF Receptor-2 (KDR), VEGF receptor-3 (sFlt4,) and PDGF-Rβ.

recombinant human extracellular domain of VEGFR-1.